Amyloid beta (A4) Precursor Protein (APP) (C-Term) Peptide

Details for Product No. ABIN700064, Supplier: Log in to see
Protein Name
  • APP
  • APP-like
  • APPL
  • Abeta
  • BcDNA:GH04413
  • CG7727
  • Dmel\\CG7727
  • EG:65F1.5
  • appl
  • aaa
  • abeta
  • abpp
  • ad1
  • appi
  • ctfgamma
  • cvap
  • pn2
  • AAA
  • ABETA
  • ABPP
  • AD1
  • APPI
  • CTFgamma
  • CVAP
  • PN-II
  • PN2
  • Abpp
  • Adap
  • Ag
  • Cvap
  • E030013M08Rik
  • betaApp
  • app
  • wu:fj34d10
  • wu:fk65e12
  • zgc:85740
  • beta amyloid protein precursor-like
  • amyloid beta (A4) precursor protein
  • amyloid beta (A4) precursor protein a
  • beta amyloid protein precursor
  • Appl
  • APP
  • app
  • App
  • appa
  • LOC100009546
Protein Region
C-Term
Source
Synthetic
Peptide Type
Synthetic
Application
Blocking Peptide (BP)
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Specificity The synthetic peptide sequence used to generate the antibody AP6306b was selected from the C-term region of human APP . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Background APP is a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy).
Restrictions For Research Use only
Storage 4
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Background publications Zhou, Su, Li, Liu, Ryder, Wu, Gonzalez-DeWhitt, Gelfanova, Hale, May, Paul, Ni: "Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho." in: Science (New York, N.Y.), Vol. 302, Issue 5648, pp. 1215-7, 2003 (PubMed).

Murakami, Irie, Morimoto, Ohigashi, Shindo, Nagao, Shimizu, Shirasawa: "Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease." in: The Journal of biological chemistry, Vol. 278, Issue 46, pp. 46179-87, 2003 (PubMed).

Kim, Kim, Lee, Choi, Kim, Huh, Lee, Han, Rha: "Amyloid beta peptide (Abeta42) activates PLC-delta1 promoter through the NF-kappaB binding site." in: Biochemical and biophysical research communications, Vol. 310, Issue 3, pp. 904-9, 2003 (PubMed).